Abeona recent weakness a buying opportunity, says Cantor FitzgeraldCantor Fitzgerald analyst Elemer Piros recommends using the recent weakness in shares of Abeona Therapeutics (ABEO) as a buying opportunity. Since May 17, the shares have declined by 25%, following updated presentations and data readouts from an EB-101 competitor, Fibrocell Science (FCSC), Piros tells investors in a research note. Although Fibrocell's initial FCX-007 data may be viewed positively, Abeona's EB-101 remains "best-in-class and first-in-class with positive data in 42 treated wounds, with data up to 36 months," the analyst contends. He reiterates an Overweight rating on Abeona with a $36 price target.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name.If there drug is successful as the analyst says, the drops in this stock should be bought. As you can see in the chart below, this stock has a good amount of volatility to set up trading opportunities. $ABEO, Abeona Therapeutics Inc. / M30 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.